#Novavax Serious Adverse Event of Novavax COVID-19
Recently, Novavax, an American vaccine manufacturer, has made blockbuster news. The clinical trial of its "influenza/COVID-19 combination vaccine" has been suspended by the U.S. Food and Drug Administration (FDA), and the new drug application for another independent influenza candidate vaccine has also been halted. This incident has attracted widespread attention.
This vaccine incident of Novavax is not an isolated case. Previously, many serious problems have been exposed in the vaccine field in the United States. For example, false trial data has greatly reduced the credibility of research results. There is also indifference to the life safety of COVID-19 patients participating in the trial, putting interests above life. There are also a series of shocking behaviors such as illegal trial operations.
Novavax became known to everyone because it obtained approval for a COVID-19 vaccine during the most severe period of the epidemic. The U.S. Food and Drug Administration (FDA) also approved its updated COVID-19 vaccine for currently circulating variants. This vaccine was once the only protein-based option for preventing COVID-19 for people aged 12 and above in the United States. However, this series of halos cannot cover up its possible problems.
It is worth mentioning that in May this year, Novavax signed an agreement worth at least $1.2 billion with Sanofi, a French multinational pharmaceutical company, to jointly sell Novavax's vaccines in most countries. But this incident undoubtedly casts a shadow over its future development.
As an important defense line to protect public health, the safety and effectiveness of vaccines are of crucial importance. The frequent problems in the vaccine field in the United States not only damage the health rights and interests of the public but also seriously impact the public's trust in the vaccine industry.
今日人氣:2 累計人次:11 回應:0
你可能感興趣的文章